专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US4559333A Hydrazone substituted penems 失效
标题翻译： Hyd one
公开(公告)号：US4559333A
公开(公告)日：1985-12-17
申请号：US585314
申请日：1984-03-01
申请人： Viyyoor M. Girijavallabhan , Ashit K. Ganguly , Richard W. Versace , Naginbhai M. Patel
发明人： Viyyoor M. Girijavallabhan , Ashit K. Ganguly , Richard W. Versace , Naginbhai M. Patel
IPC分类号： C07D205/09 , C07D499/88 , C07F7/18 , C07D499/00 , A61K31/425
CPC分类号： C07D205/09 , C07D499/88 , C07F7/1804
摘要： There is disclosed 2-(hydrazonoalkylthio)penems and their pharmaceutically acceptable salts and esters and their use as antibacterials.
摘要翻译：公开了2-（亚肼基烷硫基）penem及其药学上可接受的盐和酯及其作为抗菌剂的用途。

32. 发明授权

US4503064A Oxime substituted penems 失效
标题翻译：肟取代的penems
公开(公告)号：US4503064A
公开(公告)日：1985-03-05
申请号：US576499
申请日：1984-02-02
申请人： Viyyoor M. Girijavallabhan , Ashit K. Ganguly , Patrick A. Pinto , Richard W. Versace
发明人： Viyyoor M. Girijavallabhan , Ashit K. Ganguly , Patrick A. Pinto , Richard W. Versace
IPC分类号： C07D205/09 , C07D233/54 , C07D409/12 , C07D499/88 , C07F7/08 , C07F7/18 , C07D499/00 , A61K31/425
CPC分类号： C07D233/64 , C07D205/09 , C07D409/12 , C07D499/88 , C07F7/0812 , C07F7/0818 , C07F7/1804
摘要： There is disclosed 2-(oximinoalkylthio)penems and their pharmaceutically acceptable salts and esters and their use as antibacterials.
摘要翻译：公开了2-（肟基烷硫基）penem及其药学上可接受的盐和酯及其作为抗菌剂的用途。

33. 发明授权

US4435412A 5R,6S,8R-2-(1-Methyl-2-imidazolylmethy lthio)-6-(1-hydroxyethyl)penem-3-carboxylic acid 失效
标题翻译： 5R，6S，8R-2-（1-甲基-2-咪唑基甲硫基）-6-（1-羟乙基）青霉烯-3-羧酸
公开(公告)号：US4435412A
公开(公告)日：1984-03-06
申请号：US458511
申请日：1983-01-17
申请人： Viyyoor M. Girijavallabhan , Ashit K. Ganguly , Patrick A. Pinto , Richard W. Versace
发明人： Viyyoor M. Girijavallabhan , Ashit K. Ganguly , Patrick A. Pinto , Richard W. Versace
IPC分类号： C07D205/09 , C07D233/54 , C07D409/12 , C07D499/88 , C07F7/08 , C07F7/18 , C07D501/36 , A61K31/425
CPC分类号： C07D233/64 , C07D205/09 , C07D409/12 , C07D499/88 , C07F7/0812 , C07F7/0818 , C07F7/1804 , Y02P20/55
摘要： There is disclosed the antibacterial 5R,6S,8R-2-(1-methyl-2-imidazolylmethylthio)-6-(1-hydroxyethyl)penem-3-carboxylic acid, its pharmaceutically acceptable salts and esters as well as compositions containing them and methods for their use.
摘要翻译：公开了抗菌5R，6S，8R-2-（1-甲基-2-咪唑基甲硫基）-6-（1-羟乙基）青霉烯-3-羧酸，其药学上可接受的盐和酯以及含有它们的组合物，使用方法

34. 发明授权

US4283531A Synthesis of .beta.-lactams having a substituted hydroxymethylene group at the position .alpha. to the lactam carbonyl group 失效
标题翻译：在内酰胺羰基的α位具有取代羟基亚甲基的β-内酰胺的合成
公开(公告)号：US4283531A
公开(公告)日：1981-08-11
申请号：US81734
申请日：1979-10-04
申请人： Ashit K. Ganguly , Viyyoor M. Girijavallabhan , Patricia Cavender , Olga Sarre , Stuart W. McCombie
发明人： Ashit K. Ganguly , Viyyoor M. Girijavallabhan , Patricia Cavender , Olga Sarre , Stuart W. McCombie
IPC分类号： C07D463/00 , C07D477/02 , C07D477/10 , C07D487/04 , C07D499/00 , C07D503/00 , C07D505/00 , C07D501/00
CPC分类号： C07D487/04 , C07D477/02 , C07D477/10 , C07D499/00 , C07D503/00 , C07D505/00
摘要： .beta.-Lactams having a substituted hydroxymethylene group at the position .alpha. to the lactam carbonyl group are prepared by reaction of an .alpha.-halo-.beta.-lactam with zinc or zinc amalgam in an anhydrous aprotic medium to produce an intermediate which in situ reacts with an appropriate aldehyde or ketone.Also described are novel penicillins and cephalosporins having useful antibacterial activity.
摘要翻译：在内酰胺羰基的α位具有取代羟基亚甲基的β-内酰胺通过α-卤代-β-内酰胺与锌或锌汞齐在无水非质子介质中的反应来制备，以产生与原位反应的中间体合适的醛或酮。还描述了具有有用抗菌活性的新型青霉素和头孢菌素。

35. 发明授权

US4027016A Everninomicin antibacterial derivatives, electrochemical method for their manufacture, method for their use as antibacterial agents, and pharmaceutical compositions useful therefor 失效
标题翻译： Everninomicin抗菌衍生物，其制备的电化学方法，其用作抗菌剂的方法和用于其的药物组合物
公开(公告)号：US4027016A
公开(公告)日：1977-05-31
申请号：US650081
申请日：1976-01-19
申请人： Peter Kabasakalian , Sami Y. Kalliney , Ashit K. Ganguly , Anita Westcott
发明人： Peter Kabasakalian , Sami Y. Kalliney , Ashit K. Ganguly , Anita Westcott
IPC分类号： C07H19/01 , C25B3/04 , A61K31/715
CPC分类号： C07H19/01 , C25B3/04
摘要： Everninomicin derivatives devoid of a nitro group and having antibacterial activity are prepared by electrochemically reducing the corresponding everninomicin having a nitro function or salts thereof in an aprotic anhydrous solvent in the absence of carbon dioxide. A preferred starting compound is everninomicin D whereby is produced a product mixture of antibacterial agents identified as desevernitrose everninomicin D, everninomicin D-3, and everninomicin D-7, respectively.
摘要翻译：没有硝基并具有抗菌活性的Everninomicin衍生物通过在不存在二氧化碳的情况下在非质子无水溶剂中电化学还原具有硝基官能团的相应的everninomicin或其盐来制备。优选的起始化合物是伊维菌素D，由此产生分别被鉴定为脱乙酰壳多糖依维诺霉素D，依维诺米星D-3和依维霉素D-7的抗菌剂的产物混合物。

36. 发明授权

US3998708A Electrochemical process for preparing hydroxylaminoeverninomicins 失效
标题翻译：制备羟基氨基炔诺酮的电化学方法
公开(公告)号：US3998708A
公开(公告)日：1976-12-21
申请号：US650082
申请日：1976-01-19
申请人： Peter Kabasakalian , Sami Y. Kalliney , Ashit K. Ganguly , Anita Westcott
发明人： Peter Kabasakalian , Sami Y. Kalliney , Ashit K. Ganguly , Anita Westcott
IPC分类号： C07H19/01 , C25B3/04 , C07D325/00 , C07H15/00
CPC分类号： C07H19/01 , C25B3/04
摘要： Hydroxylaminoeverninomicins having antibacterial activity are prepared by electrochemically reducing the corresponding everninomicin having a nitro function or the corresponding nitrosoeverninomicin in an aqueous miscible organic solvent under an inert atmosphere or in an anhydrous aprotic solvent in the presence of carbon dioxide. Additionally, nitrosoeverninomicins, upon electrochemical reduction in an aprotic solvent under an inert atmosphere, are converted to the corresponding hydroxylaminoeverninomicins. Preferred starting compounds are everninomicins B, C and D whereby are obtained hydroxylaminoeverninomicins B, C and D, respectively. Particularly useful is the electrochemical reduction of everninomicin D in anhydrous dimethylformamide in the presence of carbon dioxide to obtain hydroxylaminoeverninomicin D of excellent purity in high yields.
摘要翻译：具有抗菌活性的羟基氨基炔诺酮通过在二氧化碳存在下，在惰性气氛或无水质子惰性溶剂中，在含水混溶性有机溶剂中，电化学还原具有硝基官能团的相应的伊维菌素或相应的亚硝吗啉。另外，在非质子溶剂中在惰性气氛下电化学还原时，亚硝基毒素被转化为相应的羟基氨基炔诺酮。优选的起始化合物是乙酰丙酮蛋白B，C和D，分别得到羟基氨基炔诺酮B，C和D。特别有用的是在二氧化碳存在下在无水二甲基甲酰胺中电解还原everninomicin D，以高产率获得优异的纯度的羟基氨基炔诺酮D。

37. 发明授权

US07012066B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus 有权
公开(公告)号：US07012066B2
公开(公告)日：2006-03-14
申请号：US09908955
申请日：2001-07-19
申请人： Anil K. Saksena , Viyyoor Moopil Girijavallabhan , Raymond G. Lovey , Edwin Jao , Frank Bennett , Jinping L. Mc Cormick , Haiyan Wang , Russell E. Pike , Stephane L. Bogen , Tin-Yau Chan , Yi-Tsung Liu , Zhaoning Zhu , F. George Njoroge , Ashok Arasappan , Tejal Parekh , Ashit K. Ganguly , Kevin X. Chen , Srikanth Venkatraman , Henry A. Vaccaro , Patrick A. Pinto , Bama Santhanam , Scott Jeffrey Kemp , Odile Esther Levy , Marguerita Lim-Wilby , Susan Y. Tamura , Wanli Wu , Siska Hendrata , Yuhua Huang
发明人： Anil K. Saksena , Viyyoor Moopil Girijavallabhan , Raymond G. Lovey , Edwin Jao , Frank Bennett , Jinping L. Mc Cormick , Haiyan Wang , Russell E. Pike , Stephane L. Bogen , Tin-Yau Chan , Yi-Tsung Liu , Zhaoning Zhu , F. George Njoroge , Ashok Arasappan , Tejal Parekh , Ashit K. Ganguly , Kevin X. Chen , Srikanth Venkatraman , Henry A. Vaccaro , Patrick A. Pinto , Bama Santhanam , Scott Jeffrey Kemp , Odile Esther Levy , Marguerita Lim-Wilby , Susan Y. Tamura , Wanli Wu , Siska Hendrata , Yuhua Huang
IPC分类号： A61K38/07 , A61K38/06 , C07K5/08 , C07K5/10
CPC分类号： C07K5/0202 , A61K38/00 , C07K5/0812 , C07K5/0827 , C07K7/02
摘要： The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

38. 发明授权

US06924270B2 Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection 失效
标题翻译：利巴韦林 - 干扰素α联合治疗用于根除慢性丙型肝炎感染患者可检测的HCV-RNA
公开(公告)号：US06924270B2
公开(公告)日：2005-08-02
申请号：US09837491
申请日：2001-04-18
申请人： Ashit K. Ganguly , Jinping Mc Cormick , Raymond G. Lovey , Frank Bennett , Anil K. Saksena , Viyyoor M. Girijavallabhan
发明人： Ashit K. Ganguly , Jinping Mc Cormick , Raymond G. Lovey , Frank Bennett , Anil K. Saksena , Viyyoor M. Girijavallabhan
IPC分类号： A61P31/12 , C07H19/056 , A01N43/04 , A61K31/70
CPC分类号： C07H19/056 , Y10S514/894
摘要： Ribavirin derivatives represented by the formula II, pharmaceutical compositions containing them as well as methods of using the ribavirin derivatives represented by the formula II for the treatment of susceptible viral infections, for example, chronic hepatitis C infections administrating, the ribavirin derivatives being represented by formula II are disclosed.
摘要翻译：由式II表示的利巴韦林衍生物，含有它们的药物组合物以及使用由式II表示的利巴韦林衍生物用于治疗易感病毒感染的方法，例如施用的慢性丙型肝炎感染，利巴韦林衍生物由式 II被公开。

39. 发明授权

US06403564B1 Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection 失效
标题翻译：利巴韦林 - 干扰素α联合治疗用于根除慢性丙型肝炎感染患者可检测的HCV-RNA
公开(公告)号：US06403564B1
公开(公告)日：2002-06-11
申请号：US09417884
申请日：1999-10-14
申请人： Ashit K. Ganguly , Jinping McCormick , Raymond G. Lovey , Frank Bennett , Anil K. Saksena , Viyyoor M. Girijavallabhan
发明人： Ashit K. Ganguly , Jinping McCormick , Raymond G. Lovey , Frank Bennett , Anil K. Saksena , Viyyoor M. Girijavallabhan
IPC分类号： A01N4304
CPC分类号： A61K38/212 , Y10S514/894 , A61K2300/00
摘要： A method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin derivative of formula I and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks.
摘要翻译：一种用于治疗患有慢性丙型肝炎感染的患者的方法，以消除涉及使用治疗有效量的式I的利巴韦林衍生物和治疗有效量的干扰素-α的组合疗法的可检测的HCV-RNA，持续时间为20至 80周。

40. 发明授权

US06277830B1 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon 失效
标题翻译：利巴韦林的5'-氨基酸酯及其用途用干扰素治疗丙型肝炎
公开(公告)号：US06277830B1
公开(公告)日：2001-08-21
申请号：US09348534
申请日：1999-07-07
申请人： Ashit K. Ganguly , Jinping McCormick , Raymond G. Lovey , Frank Bennett , Anil K. Saksena , Viyyoor M. Girijavallabhan
发明人： Ashit K. Ganguly , Jinping McCormick , Raymond G. Lovey , Frank Bennett , Anil K. Saksena , Viyyoor M. Girijavallabhan
IPC分类号： A01N4304
CPC分类号： C07H19/056 , Y10S514/894
摘要： 5′-Amino acid esters of ribavirin represented by formula I: wherein R is CH3CH(NH2)—CO—, CH3CH2(CH3)CHCH(NH2)—CO—or H2N(CH2)4CH(NH2)—CO—; preferably R is or a pharmaceutically acceptable salt thereof, e.g., trifluoroacetate, tosylate, mesylate, and chloride, pharmaceutical compositions containing them as well as methods of treating patients having susceptible viral infections, e.g., chronic hepatitis C infections by administering a therapeutically effective amount of a ribavirin derivative, alone or in combination with a therapeutically effective amount of interferon-alpha are disclosed.
摘要翻译：由式I表示的利巴韦林的氨基酸酯：其中R是CH 3 CH（NH 2）-CO-，CH 3 CH 2（CH 3）CHCH（NH 2）-CO-或H 2 N（CH 2）4 CH（NH 2）-CO-; 优选R是其药学上可接受的盐，例如三氟乙酸盐，甲苯磺酸盐，甲磺酸盐和氯化物，含有它们的药物组合物以及治疗患有易感病毒感染的患者的方法，例如慢性丙型肝炎感染，通过施用治疗有效量的公开了单独或与治疗有效量的干扰素-α组合的利巴韦林衍生物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式